In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring up to 15 years of follow-...

Expanding cell therapy beyond oncology opens new doors for patients—but it also introduces unique challenges in site identification and startup. From competing studies and resource limitations to regulatory nuances and cross-department collabor...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipant: Frederick DerosierDescription: Cell and gene therapy (CGT) trials are rewriting the rules of early-phase resear...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipants:  Andrea Seres, Senior Director of Strategic, Delivery and Growth in Oncology and Gene Therapy, FortreaMartin Co...

In this episode, host Laura Vidal, VP of Oncology at Fortrea, sits down with Dr. Ron Korn, Founder and Chief Medical Officer of Imaging Endpoints, to explore the evolving role of imaging in precision oncology. The conversation covers the latest...